BiomX Inc.

0.55
-0.04 (-6.11%)
At close: Apr 04, 2025, 3:59 PM
0.55
0.20%
After-hours: Apr 04, 2025, 05:43 PM EDT

Company Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.

It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).

It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials.

The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients.

In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment.

BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

BiomX Inc.
BiomX Inc. logo
Country IL
IPO Date Mar 13, 2019
Industry Biotechnology
Sector Healthcare
Employees 52
CEO Jonathan Eitan Solomon MBA

Contact Details

Address:
22 Einstein Street
Ness Ziona,
IL
Website https://www.biomx.com

Stock Details

Ticker Symbol PHGE
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001739174
CUSIP Number 09090D103
ISIN Number US09090D1037
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Jonathan Eitan Solomon MBA Chief Executive Officer & Director
Marina Wolfson CPA Chief Financial Officer & Secretary
Dr. Eran Elinav M.D., Ph.D. Scientific Founder
Dr. Merav Bassan Ph.D. Chief Development Officer
Dr. Timothy K. Lu M.D., Ph.D. Scientific Founder
Inbal Benjamini-Elran C.H.R.O
Prof. Rotem Sorek Ph.D. Scientific Founder

Latest SEC Filings

Date Type Title
Apr 01, 2025 DEFA14A Filing
Mar 31, 2025 8-K Current Report
Mar 27, 2025 DEF 14A Filing
Mar 25, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report
Mar 17, 2025 PRE 14A Filing
Mar 05, 2025 8-K Current Report
Mar 04, 2025 SCHEDULE 13G/A [Amend] Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 5 Filing